Meet The Team 
Leadership That Inspires
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem arcu amet tristique turpis purus, in. Feugiat dictumst eget sem rutrum sem. Vitae, vestibulum vel hendrerit massa duis vehicula et, vulputate.
Franklin Charles
Director of Marketing
Franklin Charles
Director of Marketing
Resources
egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026
The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure. ALISO VIEJO, Calif. — October 13, 2026 — egnite, Inc., a cardiovascular intelligence company that helps clinicians identify and manage patients with untreated heart disease, today announced that Dr. John T. Saxon, Director of the Advanced Cardiac Valve Center at University of Virginia
Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From egnite Data
BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients with severe AS and at least moderate MR. METHODS We analyzed data from 2 992 362 patients (aged ≥18 years) undergoing 5 245 904 echocardiograms at 43 US institutions
Rethinking the Aortic Stenosis Pipeline
Aortic stenosis care is shifting from a reactive to a proactive model. Emerging clinical evidence supports earlier identification, closer monitoring, and intentional patient management across the disease continuum. As treatment thresholds evolve, health systems need scalable approaches to identify at-risk patients, close treatment gaps, and ensure timely access to specialist care.